Condition
Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)
Total Trials
1
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Sparsentan
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Sparsentan1
Active Sponsors
- Travere Therapeutics, Inc.1
Top Investigators
Travere Therapeutics, Inc.
Related Conditions
- Immunoglobulin A Nephropathy1
- Iga Vasculitis1
- Alport Syndrome1
- Minimal Change Disease1
- Focal Segmental Glomerulosclerosis1